Src Inhibitor Reduces Permeability Without Disturbing Vascularization and Prevents Bone Destruction in Steroid-associated Osteonecrotic Lesions in Rabbits

Overview

Journal Sci Rep

Specialty Science

Date 2015 Mar 10

PMID 25748225

Citations 6

Authors

Yi-Xin He

Jin Liu

Baosheng Guo

Yi-Xiang Wang

Xiaohua Pan

Defang Li

Tao Tang

Yang Chen

Songlin Peng

Zhaoxiang Bian

Zicai Liang

Bao-Ting Zhang

Aiping Lu

Ge Zhang

Affiliations

Soon will be listed here.

Abstract

To examine the therapeutic effect of Src inhibitor on the VEGF mediating vascular hyperpermeability and bone destruction within steroid-associated osteonecrotic lesions in rabbits. Rabbits with high risk for progress to destructive repair in steroid-associated osteonecrosis were selected according to our published protocol. The selected rabbits were systemically administrated with either Anti-VEGF antibody (Anti-VEGF Group) or Src inhibitor (Src-Inhibition Group) or VEGF (VEGF-Supplement Group) or a combination of VEGF and Src inhibitor (Supplement &Inhibition Group) or control vehicle (Control Group) for 4 weeks. At 0, 2 and 4 weeks after administration, in vivo dynamic MRI, micro-CT based-angiography, histomorphometry and immunoblotting were employed to evaluate the vascular and skeletal events in different groups. The incidence of the destructive repair in the Anti-VEGF Group, Src-Inhibition Group and Supplement &Inhibition Group was all significantly lower than that in the Control Group. The angiogenesis was promoted in VEGF-Supplement Group, Src-Inhibition Group and Supplement &Inhibition Group, while the hyperpermeability was inhibited in Anti-VEGF Group, Src-Inhibition Group and Supplement &Inhibition Group. The trabecular structure was improved in Src-Inhibition Group and Supplement &Inhibition Group. Src inhibitor could reduce permeability without disturbing vascularization and prevent destructive repair in steroid-associated osteonecrosis.

Citing Articles

Salvianolic acid A prevented cerebrovascular endothelial injury caused by acute ischemic stroke through inhibiting the Src signaling pathway.

Liu C, Liu N, Zhang S, Ma G, Yang H, Kong L Acta Pharmacol Sin. 2020; 42(3):370-381.

PMID: 33303991 PMC: 8027612. DOI: 10.1038/s41401-020-00568-2.

Melorheostotic Bone Lesions Caused by Somatic Mutations in MAP2K1 Have Deteriorated Microarchitecture and Periosteal Reaction.

Fratzl-Zelman N, Roschger P, Kang H, Jha S, Roschger A, Blouin S J Bone Miner Res. 2019; 34(5):883-895.

PMID: 30667555 PMC: 8302214. DOI: 10.1002/jbmr.3656.

The Janus Face of VEGF in Stroke.

Geiseler S, Morland C Int J Mol Sci. 2018; 19(5).

PMID: 29734653 PMC: 5983623. DOI: 10.3390/ijms19051362.

Modulation of long-term endothelial-barrier integrity is conditional to the cross-talk between Akt and Src signaling.

Gao F, Sabbineni H, Artham S, Somanath P J Cell Physiol. 2017; 232(10):2599-2609.

PMID: 28075016 PMC: 5482788. DOI: 10.1002/jcp.25791.

Vascular endothelial growth factor: an attractive target in the treatment of hypoxic/ischemic brain injury.

Guo H, Zhou H, Lu J, Qu Y, Yu D, Tong Y Neural Regen Res. 2016; 11(1):174-9.

PMID: 26981109 PMC: 4774214. DOI: 10.4103/1673-5374.175067.

References

Bogin L, Margalit R, Mispelter J, Degani H . Parametric imaging of tumor perfusion using flow- and permeability-limited tracers. J Magn Reson Imaging. 2002; 16(3):289-99. DOI: 10.1002/jmri.10159. View

Zan L, Zhang X, Xi Y, Wu H, Song Y, Teng G . Src regulates angiogenic factors and vascular permeability after focal cerebral ischemia-reperfusion. Neuroscience. 2014; 262:118-28. PMC: 3943922. DOI: 10.1016/j.neuroscience.2013.12.060. View

Marston S, Gillingham K, Bailey R, Cheng E . Osteonecrosis of the femoral head after solid organ transplantation: a prospective study. J Bone Joint Surg Am. 2002; 84(12):2145-51. DOI: 10.2106/00004623-200212000-00004. View

So L, Lau A, Yam L, Cheung T, Poon E, Yung R . Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet. 2003; 361(9369):1615-7. PMC: 7112408. DOI: 10.1016/s0140-6736(03)13265-5. View

Henriksen K, Karsdal M, Delaisse J, Engsig M . RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem. 2003; 278(49):48745-53. DOI: 10.1074/jbc.M309193200. View

Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A . Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest. 2004; 113(6):885-94. PMC: 362122. DOI: 10.1172/JCI20702. View

Yeatman T . A renaissance for SRC. Nat Rev Cancer. 2004; 4(6):470-80. DOI: 10.1038/nrc1366. View

Duvall C, Taylor W, Weiss D, Guldberg R . Quantitative microcomputed tomography analysis of collateral vessel development after ischemic injury. Am J Physiol Heart Circ Physiol. 2004; 287(1):H302-10. DOI: 10.1152/ajpheart.00928.2003. View

Vadasz Z, Misselevich I, Norman D, Peled E, Boss J . Localization of vascular endothelial growth factor during the early reparative phase of the rats' vessels deprivation-induced osteonecrosis of the femoral heads. Exp Mol Pathol. 2004; 77(2):145-8. DOI: 10.1016/j.yexmp.2004.06.002. View

10.

Garin E, Sleasman J, RICHARD G, Iravani A, Fennell R . Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis. Eur J Pediatr. 1986; 145(5):380-3. DOI: 10.1007/BF00439243. View

11.

Parfitt A, Drezner M, Glorieux F, Kanis J, MALLUCHE H, Meunier P . Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2(6):595-610. DOI: 10.1002/jbmr.5650020617. View

12.

Soriano P, Montgomery C, Geske R, Bradley A . Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991; 64(4):693-702. DOI: 10.1016/0092-8674(91)90499-o. View

13.

van Bruggen N, Thibodeaux H, PALMER J, Lee W, Fu L, Cairns B . VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest. 1999; 104(11):1613-20. PMC: 409867. DOI: 10.1172/JCI8218. View

14.

Eliceiri B, Paul R, Schwartzberg P, Hood J, Leng J, Cheresh D . Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell. 2000; 4(6):915-24. DOI: 10.1016/s1097-2765(00)80221-x. View

15.

Boyce B, Yoneda T, Lowe C, Soriano P, Mundy G . Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 1992; 90(4):1622-7. PMC: 443211. DOI: 10.1172/JCI116032. View

16.

Hall T, Schaeublin M, Missbach M . Evidence that c-src is involved in the process of osteoclastic bone resorption. Biochem Biophys Res Commun. 1994; 199(3):1237-44. DOI: 10.1006/bbrc.1994.1363. View

17.

Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J . Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2001; 95(8):2637-44. View

18.

Kini A, Kay N, Peterson L . Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 2000; 14(8):1414-8. DOI: 10.1038/sj.leu.2401825. View

19.

Engsig M, Chen Q, Vu T, Pedersen A, Therkidsen B, Lund L . Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol. 2000; 151(4):879-89. PMC: 2169432. DOI: 10.1083/jcb.151.4.879. View

20.

Violette S, Guan W, Bartlett C, Smith J, Bardelay C, Antoine E . Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption. Bone. 2001; 28(1):54-64. DOI: 10.1016/s8756-3282(00)00427-0. View